Next-Generation Sequencing Liquid Biopsy-Guided Osimertinib Rechallenge in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients

[1] Lazzari C(2020)Mechanisms of resistance to osimertinib J Thorac Dis 12 2851-50

[2] Gregorc V(2020)Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC N Engl J Med 382 41-640

[3] Karachaliou N(2017)Osimertinib or platinum–pemetrexed in EGFR T790M-positive lung cancer N Engl J Med 376 629-5140

[4] Rosell R(2016)Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity Clin Cancer Res 22 5130-429

[5] Santarpia M(2010)Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib Oncology 79 423-463

[6] Ramalingam SS(2012)Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib Clin Lung Cancer 13 458-127

[7] Vansteenkiste J(2012)Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study Lung Cancer 77 121-1038

[8] Planchard D(2018)A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403 Cancer Chemother Pharmacol 82 1031-180

[9] Cho BC(2019)Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer JAMA Oncol. 5 173-4700

[10] Gray JE(2015)Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. Hoheisel JD, editor PLoS ONE 10 e0140712-37

[1] Lazzari C(2020)Mechanisms of resistance to osimertinib J Thorac Dis 12 2851-50

[2] Gregorc V(2020)Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC N Engl J Med 382 41-640

[3] Karachaliou N(2017)Osimertinib or platinum–pemetrexed in EGFR T790M-positive lung cancer N Engl J Med 376 629-5140

[4] Rosell R(2016)Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity Clin Cancer Res 22 5130-429

[5] Santarpia M(2010)Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib Oncology 79 423-463

[6] Ramalingam SS(2012)Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib Clin Lung Cancer 13 458-127

[7] Vansteenkiste J(2012)Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study Lung Cancer 77 121-1038

[8] Planchard D(2018)A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403 Cancer Chemother Pharmacol 82 1031-180

[9] Cho BC(2019)Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer JAMA Oncol. 5 173-4700

[10] Gray JE(2015)Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. Hoheisel JD, editor PLoS ONE 10 e0140712-37